https://scholars.lib.ntu.edu.tw/handle/123456789/641209
標題: | Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study | 作者: | Peyrin-Biroulet, Laurent Allegretti, Jessica R Rubin, David T Bressler, Brian Germinaro, Matthew Huang, Kuan-Hsiang Gary Shipitofsky, Nicole Zhang, Hongyan Wilson, Rebbecca Han, Chenglong Feagan, Brian G Sandborn, William J Panés, Julian Hisamatsu, Tadakazu Lichtenstein, Gary R Sands, Bruce E Dignass, Axel SHU-CHEN WEI |
關鍵字: | Advanced Therapy; Interleukin-23p19 Subunit Antagonist; QUASAR; Ulcerative Colitis | 公開日期: | 十二月-2023 | 卷: | 165 | 期: | 6 | 起(迄)頁: | 1443 | 來源出版物: | Gastroenterology | 摘要: | The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) with prior inadequate response and/or intolerance to corticosteroids, immunosuppressants, and/or advanced therapy. |
URI: | https://www.scopus.com/record/display.uri?eid=2-s2.0-85174843526&doi=10.1053%2fj.gastro.2023.08.038&origin=inward&txGid=15e89240987763955bfaaf167d395854 https://scholars.lib.ntu.edu.tw/handle/123456789/641209 |
ISSN: | 00165085 | DOI: | 10.1053/j.gastro.2023.08.038 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。